Latest News and Press Releases

Amryt Granted Orphan Drug Designation by the FDA for AP103 DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia DUBLIN, Ireland, and Boston MA, December 17, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global,...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil DUBLIN, Ireland, and Boston MA, December 09, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

Amryt Announces $40m Private Placement with Leading Biotech Investors DUBLIN, Ireland, and Boston MA, December 8, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

AMRYT REPORTS RECORD Q3 2020 RESULTS 19% YoY revenue growth in the quarter to $49.3M Raising full year revenue guidance to $180M - $182M Both metreleptin and lomitapide driving revenue...

AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA LATE-BREAKING ORAL PRESENTATION AT THE 29TH EADV (VIRTUAL) CONGRESS ON OCTOBER 31 Virtual Analyst &...

AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR LOJUXTA® ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)  DUBLIN, Ireland, and Boston MA,...

AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020 DUBLIN, Ireland, and Boston MA, October 14 2020,  Amryt (Nasdaq: AMYT, AIM: AMYT), a global,...